Sangamo (SGMO) May Be Next Biotech Takeover - BusinessWeek

According to BusinessWeek's Inside Wall Street column, Navdeep Jaikaria, a biotech analyst at Rodman & Renshaw, thinks Sangamo (Nasdaq: SGMO) could be the next biotech takeover following the recent string of deals. The company harnesses a natural cellular process aimed at regulating or modifying disease-related genes in humans and other organisms and already has partnerships with Pfizer (NYSE: PFE), Dow Chemical (NYSE: DOW) and Edwards Lifesciences (NYSE: EW).